Xu‐Sheng Liu

916 total citations
42 papers, 638 citations indexed

About

Xu‐Sheng Liu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Insect Science. According to data from OpenAlex, Xu‐Sheng Liu has authored 42 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 17 papers in Pulmonary and Respiratory Medicine and 12 papers in Insect Science. Recurrent topics in Xu‐Sheng Liu's work include RNA modifications and cancer (23 papers), Ferroptosis and cancer prognosis (15 papers) and Epigenetics and DNA Methylation (10 papers). Xu‐Sheng Liu is often cited by papers focused on RNA modifications and cancer (23 papers), Ferroptosis and cancer prognosis (15 papers) and Epigenetics and DNA Methylation (10 papers). Xu‐Sheng Liu collaborates with scholars based in China, United States and Hong Kong. Xu‐Sheng Liu's co-authors include Zhi‐Jun Pei, Yan Gao, Xiaoyu Liu, Lingling Yuan, Jia‐Lin Wang, Yu‐Feng Wang, Xiao‐Qiang Yu, Zhen He, Munmun Chowdhury and Yuzhen Lu and has published in prestigious journals such as Journal of Biological Chemistry, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Xu‐Sheng Liu

41 papers receiving 631 citations

Peers

Xu‐Sheng Liu
Indira Paddibhatla United States
Xiao-Lu Teng China
Sang-Ho Yoon South Korea
Hong Sun Kim South Korea
Muhammad Nadeem Abbas China
Xiaolong Dong China
Sven M. Lange United Kingdom
Julia Coronella United States
Linhong Li United States
Indira Paddibhatla United States
Xu‐Sheng Liu
Citations per year, relative to Xu‐Sheng Liu Xu‐Sheng Liu (= 1×) peers Indira Paddibhatla

Countries citing papers authored by Xu‐Sheng Liu

Since Specialization
Citations

This map shows the geographic impact of Xu‐Sheng Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu‐Sheng Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu‐Sheng Liu more than expected).

Fields of papers citing papers by Xu‐Sheng Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xu‐Sheng Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu‐Sheng Liu. The network helps show where Xu‐Sheng Liu may publish in the future.

Co-authorship network of co-authors of Xu‐Sheng Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Xu‐Sheng Liu. A scholar is included among the top collaborators of Xu‐Sheng Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xu‐Sheng Liu. Xu‐Sheng Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Liu, Xu‐Sheng, Yuxuan Chen, Yangyang Wang, et al.. (2024). TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association. Scientific Reports. 14(1). 4042–4042. 8 indexed citations
4.
Wang, Jia‐Lin, et al.. (2023). An entomopathogenic fungus exploits its host humoral antibacterial immunity to minimize bacterial competition in the hemolymph. Microbiome. 11(1). 116–116. 19 indexed citations
5.
Gu, Yue-Yu, Xu‐Sheng Liu, & Hui Y. Lan. (2023). Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs. Molecular Therapy. 32(2). 313–324. 21 indexed citations
6.
Zhang, Yaohua, Xu‐Sheng Liu, Yan Gao, et al.. (2023). SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters. Lung Cancer. 188. 107449–107449. 5 indexed citations
7.
Liu, Xu‐Sheng, Lingling Yuan, Yan Gao, et al.. (2023). DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma. Journal of Translational Medicine. 21(1). 574–574. 5 indexed citations
8.
Liu, Xu‐Sheng, Yan Gao, Xueqin Chen, et al.. (2022). Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma. Frontiers in Genetics. 13. 835265–835265. 21 indexed citations
9.
Liu, Xu‐Sheng, Jing Zeng, Xueqin Chen, et al.. (2022). SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA. Frontiers in Cell and Developmental Biology. 10. 853596–853596. 35 indexed citations
10.
Gao, Yan, Lingling Yuan, Jing Zeng, et al.. (2022). eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma. Journal of Translational Medicine. 20(1). 303–303. 10 indexed citations
11.
Zhang, Yaohua, Jing Zeng, Xu‐Sheng Liu, et al.. (2022). ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma. Frontiers in Endocrinology. 13. 1013238–1013238. 5 indexed citations
12.
Gao, Yan, Xu‐Sheng Liu, Jing Zeng, et al.. (2022). Comprehensive Analysis of SLC17A9 and Its Prognostic Value in Hepatocellular Carcinoma. Frontiers in Oncology. 12. 809847–809847. 6 indexed citations
13.
Liu, Xiaoyu, Yan Gao, Xu‐Sheng Liu, et al.. (2022). High expression of HNRNPR in ESCA combined with 18F-FDG PET/CT metabolic parameters are novel biomarkers for preoperative diagnosis of ESCA. Journal of Translational Medicine. 20(1). 450–450. 6 indexed citations
14.
Yuan, Lingling, Yan Gao, Xu‐Sheng Liu, et al.. (2021). 18F-FDG PET/CT metabolic parameters correlate with EIF2S2 expression status in colorectal cancer. Journal of Cancer. 12(19). 5838–5847. 9 indexed citations
15.
Liu, Xu‐Sheng, Yan Gao, Libing Wu, et al.. (2021). Comprehensive Analysis of GLUT1 Immune Infiltrates and ceRNA Network in Human Esophageal Carcinoma. Frontiers in Oncology. 11. 665388–665388. 27 indexed citations
16.
Liu, Xu‐Sheng, Yijia Chen, Fuyan Li, et al.. (2021). Comprehensive Analysis of Hexokinase 2 Immune Infiltrates and m6A Related Genes in Human Esophageal Carcinoma. Frontiers in Cell and Developmental Biology. 9. 715883–715883. 14 indexed citations
17.
Yuan, Lingling, et al.. (2020). Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 48(3). 904–912. 12 indexed citations
18.
19.
Chen, Lei, et al.. (2017). 20-Hydroxyecdysone promotes release of GBP-binding protein from oenocytoids to suppress hemocytic encapsulation. Insect Biochemistry and Molecular Biology. 92. 53–64. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Indira Paddibhatla Breakdown of academic impact, for papers by Xiao-Lu Teng Breakdown of academic impact, for papers by Sang-Ho Yoon Breakdown of academic impact, for papers by Hong Sun Kim Breakdown of academic impact, for papers by Muhammad Nadeem Abbas Breakdown of academic impact, for papers by Xiaolong Dong Breakdown of academic impact, for papers by Sven M. Lange Breakdown of academic impact, for papers by Julia Coronella Breakdown of academic impact, for papers by Linhong Li
Rankless by CCL
2026